Home Page
Skip navigation links
About Us
Business Assistance
News & Events
Facts & Maps
Skip Navigation LinksMaryland Biotechnology Center > News Events

Maryland News 


Jan   Feb   Mar   Apr   May   Jun   Jul   Aug   Sept   Oct   Nov   Dec 


NIH names Dr. Jon Lorsch director of the National Institute of General Medical Sciences
Press Release
National Institutes of Health Director Francis S. Collins, M.D., Ph.D., announced today the selection of Jon R. Lorsch, Ph.D., as Director of the National Institute of General Medical Sciences. Dr. Lorsch is expected to join the NIH this summer. Read More...

BioHealth Innovation aims to help Maryland biotechs land government deals
Baltimore Business Journal
BioHealth Innovation Inc. in Rockville is launching a program to help small life sciences companies in Central Maryland land more government grants.

New Spray Product Takes Aim at Salmonella on Poultry
Food Safety News
“A sneaky germ.” That’s how the U.S. Centers for Disease Control and Prevention describes Salmonella
. The agency follows that uncomplimentary description with a warning that Salmonella can contaminate more than just poultry and eggs. “It sneaks its way into many foods — ground beef, pork, tomatoes, sprouts — even peanut butter,” says the CDC site. 

With Nacy’s guidance, Sequella taking on life-threatening diseases
For 17 years, Carol A. Nacy was a career scientist and science manager for the Walter Reed Army Institute of Research, studying tropical, infectious diseases and publishing more than 100 papers. Read More...

Johns Hopkins researchers use a type of stem cells from human adipose tissue to chase migrating cancer cells
Press Release
In laboratory studies, Johns Hopkins researchers say they have found that stem cells from a patient’s own fat may have the potential to deliver new treatments directly into the brain after the surgical removal of a glioblastoma, the most common and aggressive form of brain tumor.

Neuralstem CEO, Richard Garr, Named To "Top 50 Global Stem Cell Influencers"
Press Release
Neuralstem, Inc. announced that CEO and President, Richard Garr, was listed as the 15th most influential person in the stem field in  the "Top 50 Global Stem Cell Influencers," published by Total BioPharma,  a division of Terrapinn, in advance of the World Stem Cells & Regenerative Medicine Congress 2013, in May.

Noxilizer CEO: SAIAN aquisition a 'natural complement' for company
Baltimore Business Journal
Noxilizer Inc., a Baltimore sterilization company led by CEO Lawrence Bruder, has come a long way in a short time. Just this past November the company was celebrating its first U.S. customer for its signature nitrogen dioxide sterilization system, RTS 360 Industrial NO2 Sterilizer. Read More...

Noxilizer Acquires Japanese-Based SAIAN Corporation Assets And Expands Nitrogen Dioxide Sterilization Product Line For Global Life Science Marketplace
Press Release
Noxilizer, Inc. and SAIAN Corporation announced today Noxilizer’s asset acquisition of SAIAN Corporation. Both companies have been involved in developing nitrogen dioxide as a sterilization solution for pharmaceutical, biotech and medical device companies, as well as hospitals. Read More...

Intralytix Wins Regulatory Approval For Phage-Based Food Safety Product Effective Against Salmonella
Press Release
Intralytix, Inc. announced that its latest food safety product, SalmoFresh™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA). Read More...

Sequestration a blow to life sciences
Fierce Pharma
A total of $85 billion in across-the-board U.S. government spending cuts will be triggered in the absence of a last-minute Congressional deal to delay or end the threat of sequestration.  Read More...

Sequestration puts speed bumps in drug review fast lane
Fierce Pharma
Drugmakers paid a toll to build the FDA fast lane for drug approval, only to find it full of speed bumps created by the sequestration law that went into effect.  Read More...


New Bioterrorism Vaccine Gets First Test In Humans
PR Newswire
Integrated BioTherapeutics (IBT) announces the initiation of a Phase 1 clinical trial testing the safety and immunogenicity of its staphylococcal enterotoxin B vaccine "STEBVAX" in healthy adults. Read More...

Stem cell biotech Osiris Therapeutics wins overseas
Osiris Therapeutics announced a couple of legal and regulatory victories this week. Read More...

Hopkins researcher receives new award to spotlight scientists
Baltimore Sun
A Johns Hopkins doctor known for his work using genetics to test for and treat colon and other cancers is one of the inaugural winners of a new $3 million award meant to spotlight scientists not known to the average person.

Cytomedix To Raise Up To $27.5 Million As Part Of A Comprehensive 2013 Financing Plan
Press Release
Cytomedix, Inc., a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today the execution of a comprehensive financing plan for 2013.  Included in these executed transactions is a tranched $7.5 million senior secured term loan facility, a $5 million equity raise, and a $15 million committed equity facility. Read More...

United Therapeutics heads back to the FDA
Four months after the Food and Drug Administration shot down United Therapeutics’ application to market a tablet version of its drug for pulmonary arterial hypertension, the Silver Spring company has reapplied to the regulatory agency. Read More...

NW BIO Takes Next Steps In Moving Forward With Its Phase III Brain Cancer Trial In Europe
Press Release
Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that, building upon nearly three years of manufacturing development, regulatory processes and clinical preparations in Europe, the Company has named a leading international contract research organization (CRO) to manage the Company’s 312-patient Phase III clinical trial for Glioblastoma multiforme (GBM) brain cancer in Europe. Read More... 

Life Technologies Receives FDA 510(k) Clearance For Diagnostic Use Of Sanger Sequencing Platform And HLA Typing Kits
Life Technologies, a global co w/ R&D facilities in Frederick, receives FDA 510(k) clearance for Dx use of CE Sequencing Systems & HLA Assay.

Actavis Details Strategy for Continued Long-Term Growth
Press Release
Actavis, Inc. (NYSE: ACT), formerly Watson Pharmaceuticals, Inc., today provides an in-depth look into the newly combined company’s global commercial operations, diversified business structure and outlook for continued longterm growth during its fourth annual Investor Meeting in New York.  Read More....


Emergent BioSolutions Initiates Phase 2 Study in Pursuit of a Post-Exposure Prophylaxis Indication for BioThrax
Press Release
Emergent BioSolutions Inc. today announced the initiation of a Phase 2 study designed to evaluate non-interference of BioThrax® (Anthrax Vaccine Adsorbed) when administered in conjunction with antibiotics.

MaxCyte® VLX and STX Transient Transfection Systems Are Acquired by Paragon Bioservices for Use in Vaccine and Protein Manufacturing
Press Release
MaxCyte, Inc., the pioneer in scalable, high performance transient transfection systems, is pleased to announce that Paragon Bioservices has acquired both the MaxCyte VLX® Large Scale Transfection System and the MaxCyte STX® Scalable Transfection System for use in contract manufacturing of recombinant proteins, antibodies, viral vectors, vaccines, and VLPs.

Scientists Seek Stem Cell Cure For Spinal Cord Injuries
Neuralstem, a Rockville-based biotech company, has just been approved by the FDA to begin implanting stem cells into people with spinal cord injuries. While there's a long scientific journey ahead, this trial could mean hope for paraplegic and quadriplegic patients all over the world.

BARDA Continues Novavax' Influenza Vaccine Programs Following In-Process Review
Novavax, Inc. today announced that the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) has completed an In-Process Review (IPR) of Novavax' contract covering the company's recombinant virus-like particle (VLP) vaccine candidates for pandemic and seasonal influenza. Read More...

At CytImmune, Lawrence Tamarkin is on a gold rush
Lawrence Tamarkin was on the brink of a discovery that could change the paradigm of cancer treatment delivery when the Great Recession forced his company to slow down. But with some key contacts and flexibility, Tamarkin says he is now ready to show the world what his technology can do.

Despite growing demand, MedImmune still has flu vaccines on hand
With a more virulent-than-usual influenza season well under way, MedImmune says it’s ready to meet vaccine demands, even as it prepares to release a more protective, four-strain vaccine next season.

Rexahn Pharmaceuticals names new CEO
Washington Business Journal
Rockville-based Rexahn Pharmaceuticals has named Dr. Peter Suzdak as chief executive officer. Read More...

Bahija Jallal to replace Peter Greenleaf as head of MedImmune
Washington Business Journal
MedImmune executive Bahija Jallal will be the new chief of the Gaithersburg biotech under a leadership shuffle by parent company AstraZeneca.

Neuralstem Receives FDA Approval To Commence Spinal Cord Injury Trial
Press Release
Neuralstem, Inc. announced that it received approval from the United States Food and Drug Administration (FDA) to commence a Phase I safety trial of its lead cell therapy candidate, NSI-566, in chronic spinal cord injury patients. This open-label, multi-site study, will enroll up to eight patients with thoracic spinal cord injuries (T2-T12), who have an American Spinal Injury Association (AIS) A level of impairment,  between one and two years after injury. Read More...

CytImmune and AstraZeneca to Research Potential New Nanomedicine for Cancer
Press Release
CytImmune and AstraZeneca have entered into an agreement to study the feasibility of a new cancer nanomedicine that will bind an oncology compound from AstraZeneca to CytImmune’s CYT--‐6091 nanomedicine platform.

Daiichi Sankyo and Amplimmune Announce Strategic Alliance to Develop AMP-110 Therapy for Autoimmune Disease
Press Release
Daiichi Sankyo, Co., Ltd. and Amplimmune, Inc. announced today that they have entered into a broad strategic collaboration to develop a new therapeutic protein, AMP-110 (B7-H4 fusion protein). The collaboration will focus on development of AMP-110, a potential immune modulation therapy for autoimmune diseases. Read More...

Maryland Innovation Initiative Awards Funding to First Three Research Projects
Press Release
The Maryland Innovation Initiative (MII), which accelerates commercialization and technology transfer from university labs to start-up companies, announced its first three awards today, totaling $299,678. These three awards were given to BOSS Medical LLC, a university start-up company, and two Johns Hopkins University faculty members. The three awards were given through the Innovation Commercialization Program, which provides funding to support the commercialization of qualified university technologies at three distinct stages: pre-commercial translational research (Phase I), commercialization planning (Phase II) and early-stage product development (Phase III). Read More...

MacroGenics and Gilead Sciences Enter Strategic Alliance to Develop and Commercialize Four DART™ Products
Press Release
MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced it has entered into a license agreement with Gilead Sciences, Inc. for the development and commercialization of Dual-Affinity Re-Targeting (DART™) products directed at up to four undisclosed targets. MacroGenics’ DART technology is a proprietary, bi-specific antibody platform in which a single recombinant molecule is able to target two different antigens.

Telcare is tied for 3rd place at CES
Telcare is tied for 3rd place in the Last Gadget Standing competition at the 2013 Consumer Electronics Show. Telcare is being recognized for their wireless glucose blood meter.  To cast your vote, click here.

Immunovaccine Reports Positive Results from Ongoing Study of DepoVax™-Based Anthrax Vaccines
Press Release
Immunovaccine Inc., a clinical stage vaccine company, today announced positive results from an immunogenicity study that evaluated anthrax vaccines formulated in the Company’s DepoVax™ platform. Read More...


Plant Sensory Systems Awarded $1.8M from ARPA-E to Engineer Beets for Biofuel
The award will support a three-year program to develop an enhanced energy (sugar) beet, optimized for biofuel productions.  Read More

Controversial FDA Official Tom Laughren Retires
One of the more controversial figures at the FDA over the past decade quietly retired late last month. Tom Laughren, who was the director of the Division of Psychiatry Products in the Office of New Drugs in the Center for Drug Evaluation and Research, departed the FDA after spending nearly 20 years at the agency, an FDA spokeswoman confirms. Read More...

Cytomedix Inc. Announces Positive Results With Angel® cPRP in Veterinary Application
Cytomedix, Inc., a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that positive data on the Angel® cPRP system in a veterinary application -- treatment of persistent mating induced endometritis (PMIE) in mares -- were recently presented at the 3rd annual conference of the North American Veterinary Regenerative Medicine Association (NAVRMA) in Savannah, GA.

Profectus HIV vaccine advances in trial
A Baltimore biotech reported that its experimental HIV vaccine showed promising results in a phase 1 clinical study. Read More...

Medical device makers to be hit with tax in 2013
Washington Business Journal
Starting Jan. 1, medical device manufacturers must pay a new 2.3 percent excise tax on their gross revenues, regardless of profits, to raise $1.8 billion in federal revenue in 2013 and $20 billion through 2019, as part of the health care reform legislation. Read More...


Teva Pharmaceuticals Industries boosts stake in Rexahn Pharmaceuticals
Washington Business Journal
Teva Pharmaceuticals Industries Ltd. has boosted its stake in Rockville-based Rexahn Pharmaceuticals Inc. and will increase its involvement in developing Rexahn's lead anti-cancer drug. Read More...

MdBio Foundation names former Washington Redskins exec new CEO
Washington Business Journal
A former Washington Redskins charity director has joined MdBio Foundation as its new CEO. Brian Gaines, former executive director of the Washington Redskins Charitable Foundation will oversee MdBio Foundation’s daily operations, fundraising and development, the Baltimore Business Journal reported.

Noxilizer hits milestone with first sale of sterilization system
Baltimore Business Journal
Baltimore biotech firm Noxilizer sold its first sterilization system to an Indianapolis company, a deal that could be worth up to $340,000 over the next three years and sets the stage for expanding the company’s operations from services to products. Read More...

Tech Council of Maryland chief Art Jacoby to depart in February
Washington Business Journal
Art Jacoby, who set an ambitious agenda for the Tech Council of Maryland following his quiet promotion to CEO this summer, will leave the trade group early next year. Read More...

Biotech veterans take reins at Biota — the new Nabi
Biota Pharmaceuticals — formerly Nabi Biopharmaceuticals — has a new team at the top. Read More...

R. Don Elsey out as Emergent BioSolutions CFO
Washington Business Journal
R. Don Elsey has resigned as chief financial officer of Emergent BioSolutions Inc., a role he’s held since 2006, the Rockville biotech announced Monday. Read More...

MedImmune creating drug pipeline for AstraZeneca
The Baltimore Sun
MedImmune leaders say they are entering a prime phase in drug development, with several projects moving into final patient trials and a growing share of AstraZeneca's overall drug pipeline. Given intense competition in the industry, success will depend on how each gamble pays off in the laboratory. Read More...

Synthetic Biologics, Inc. (AEN) Announces $10.8 Million Financing
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, announced that it has entered into definitive stock purchase agreements with accredited investors to raise approximately $10.8 million in a private placement financing.  Read More...

Another Supernus Pharmaceuticals (SUPN) Epilepsy Drug Gets FDA Nod
Supernus Pharmaceuticals, Inc. (SUPN), a specialty pharmaceutical company, received approval from the Food & Drug Administration (the "FDA") for Oxtellar XR , a novel once-daily extended release formulation of oxcarbazepine (formerly known as SPN-804). 


United Therapeutics drug rejected by FDA
Baltimore Business Journal
United Therapeutics Corp.'s new drug application for a tablet version of its treatment for pulmonary arterial hypertension has been rejected by the Food and Drug Administration, more than a year after disappointing results in late-stage clinical trials.  Read More...

Another Supernus Pharmamaceuticals (SUPN) Epilepsy Drug gets FDA Nod
Supernus Pharmaceuticals, Inc. (SUPN), a specialty pharmaceutical company, received approval from the Food & Drug Administration (the "FDA") for Oxtellar XR , a novel once-daily extended release formulation of oxcarbazepine (formerly known as SPN-804). Read More...

GlycoMimetics announces the publication of a scientific paper in Nature Medicine
Press Release
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, announced today that preclinical data related to its lead drug candidate, GMI-1070, has been published in the current issue of Nature Medicine. Read More...

Aeras Global TB Vaccine Foundation, GlaxoSmithKline (GSK) Collaborate onTB Vaccine
Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK's proprietary M72 antigen and AS01E* adjuvant.  Read More...

MedImmune (AZN) Inks Pact With Two Leading Cancer Institutes to Advance R&D
The Cancer Research Institute (CRI), the Ludwig Institute for Cancer Research and MedImmune, the global biologics arm of AstraZeneca, today announced that they have signed a collaboration agreement to advance the research of immunotherapy in cancer.  Read More...

UMBC researchers win $1.4M grant for diabetes study
Baltimore Business Journal
Two researchers at the University of Maryland, Baltimore County received a nearly $1.4 million grant from the National Institutes of Health to study how people with diabetes manage the condition.  Read More...

Baxter leads Gliknik Series B Investment
Press Release
Gliknik Inc., a privately held biopharmaceuticals company creating new therapies for cancer and immune / inflammatory disorders, today announced that it has raised $4.9 million in Series B Financing. Baxter Ventures, an initiative created in 2011 by Baxter International Inc., led the Series B raise and is joined by existing investors. Read More...


William E. Proudford Sickle Cell Fund Honors Glycomimetics, Inc. with "Unsung Hero" Award
Press Release
GlycoMimetics, Inc. a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, announced today that the William E. Proudford Sickle Cell Fund presented the company with its 2012 Unsung Hero Award.  Read More...

MedImmune may expand Gaithersburg Campus
Baltimore Business Journal
MedImmune executives hinted this week that an expansion of the Gaithersburg-based biotech's campus may be coming soon.  Read More... 

MacroGenics and Serview Enter Broad Strategic Alliance to Develop and Commercialize Three Anti-Cancer DARTTM products
MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, France's largest privately‐held pharmaceutical company, announced today that they have entered into an option agreement for the development and commercialization of Dual‐Affinity Re‐Targeting (DARTTM) products directed at three undisclosed tumor targets.  Read More...

MacroGenics, Inc. Could Earn More Than $1 Billion Through New Servier Alliance
MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, France's largest privately-held pharmaceutical company, announced today that they have entered into an option agreement for the development and commercialization of Dual-Affinity Re-Targeting (DART) products directed at three undisclosed tumor targets.  Read More...

Army awards $2.67M to startup to develop miniature device to assess TBI
MedCity News
A Bethesda, Maryland startup BrainScope has been awarded a $2.67 million contract over two years to develop a miniature, hand-held, non-invasive medical devices that can rapidly evaluate traumatic brain injury in the field. Read More...

NeuralStem Inc.
Gains on Stem Cell Therapy for Paralyzed Rats
Neuralstem, Inc. announced that its neural stem cells were part of a study, "Long-Distance Growth and Connectivity of Neural Stem Cells After Severe Spinal Cord Injury: Cell-Intrinsic Mechanisms Overcome Spinal Inhibition," published online today in a leading scientific journal CELL (
http://www.cell.com/current). 

NeuralStem Inc. to Raise $7.0 Million in Registered Direct Offering
Neuralstem, Inc. (NYSE MKT: CUR) today announced the pricing of a registered direct offering of 7,000,000 shares of its common stock, offered at a price to the public of $1.00 per share. The gross proceeds to Neuralstem from this offering are expected to be $7.0 million, before deducting placement agent fees and other estimated offering expenses payable by Neuralstem. The offering is expected to close on or about September 19, 2012, subject to customary closing conditions. 

Intralytix Awarded Phase II Grant for Managing Salmonella in Food
Press Release
Intralytix, Inc. announced today that it has been awarded a grant under a National Institute of Food And Agriculture (NIFA) / United States Department of Agriculture (USDA) Small Business Innovative Research (SBIR) Grants Program for the development of a phage preparation for reducing or eliminating Salmonella contamination in foods. 
Read More....

The Symposium on Advanced Wound Care (SWAC Fall)
Poster presenters will be available September 13 from 5:30 p.m. to 6:15 p.m. local time, and posters will be available for viewing September 12 and September 13 from 8:00 a.m. to 4:00 p.m. local time.  The following posters highlighting Cytomedix’s PRP technology will be presented at SAWC Fall 2012.

·         Aged Spinal Cord Injury Veterans with Recalcitrant Pressure Ulcers Treated with Platelet-Rich Plasma Gel by Natalie Tukpah, RN, CWOCN and Karen Evans, M.D., Veterans Affairs Medical Center, Washington D.C. Poster Number CS-042.

Healing Complex, Severe Diabetic and Ischemic Wounds in Japan Using Platelet-Rich Plasma Gel by Chugo Rinoie, DPM, ABPO, CWS, Chief of Podiatric Surgery, Wound Healing Center, Methodist Hospital of Southern California, Arcadia, Calif., and Medical Director, Millennia Wound Management, Inc., Los Angeles.  Poster Number CR-021.

 Advancing Wound Healing Trajectory with Platelet Rich Plasma Gel in Stalled NPWT Wounds by Janice Wilson, RN, CWOCN and Karl Branch, RN, Asheville Specialty Hospital, Asheville, N.C.  Poster Number CR-029. More Info

Foodem gets $75,000 investment from TEDCO to build online wholesale food portal
Baltimore Sun
One of the latest tech startups to get a footing in Baltimore is Foodem, a website started by a University of Maryland College Park grad a few years ago that aims to build a transparent marketplace for commercial food buyers and distributors. 

Akonni Gets $500K SBIR Grant for Array Consumables
GenomeWeb Daily News
Akonni Biosystems today said that it has received a $498,780 Phase 2 SBIR award from the National Science Foundation to further develop its Lab-on-a-Film microarray consumable technology.


KeyGene, AGI Ink Deal Covering Whole Genome Profiling Technology
Agricultural genomics firm KeyGene and the Arizona Genome Institute today announced an agreement for the use of the Wageningen, Netherlands-based firm's Whole Genome Profiling method in sequencing-based physical mapping projects. Read More...

Telcare Raises $25.5 Million in Financing, Led by Sequoia Capital
Press Release
Telcare, Inc., developer of the first FDA-cleared wireless glucose monitoring system for people with diabetes, announced today that it has secured $25.5 million in equity funding as the first close of a Series B financing led by Sequoia Capital, Menlo Park, CA. Read More...

Fyodor Biotechnologies awarded a National Science Foundation SBIR Grant
Press Release
Fyodor Biotechnologies, a Baltimore-based diagnostic and biopharmaceutical company, announced today that the National Science Foundation has awarded the company a Small Business Innovation Research (SBIR) Phase I grant. With the $150,000 funding, Fyodor plans to develop a novel recombinant antibody to be used in a urine-based test for the point-of-need detection of Leptospirosis. Read More...

Fyodor Biotechnologies expands within University of Maryland BioPark
Press Release
Fyodor Biotechnologies Inc. announced today that it has expanded its office and laboratory space at the University of Maryland BioPark in Baltimore, moving from the BioPark’s BioInnovation Center (BIC) at 801 West Baltimore Street to the expanded BioInnovation Center across the street at 800 West Baltimore Street. The move is prompted by Fyodor’s advancing research and development activities, including those related to its urine-based malaria diagnostic assay. Read More...


Osiris shares tumble on $4.3M second-quarter loss
Baltimore Business Journal
Osiris Therapeutics Inc. swung to a $4.3 million loss in the second quarter on less revenue from research agreements and royalties. Read More...

Drug from Mediterranean weed kills tumor cells in mice
The JHU Gazette
Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anti-cancer drug designed to travel—undetected by normal cells—through the bloodstream until activated by specific cancer proteins. Read More...

Psyadon’s Chipkin has ‘passion’ for his experimental drug
Richard E. Chipkin is devoting his professional life to the success of his baby. Read More...

Top of the List: Baltimore biotech companies
Baltimore Business Journal
Each week we give you a countdown of the top five to 10 companies or organizations from one of our Lists publishing in our Friday paper. This week it’s the “Largest biotechnology companies in the Baltimore area.” Read More...

Baltimore biotechs seek staff
Baltimore Business Journal
If you’ve recently asked yourself, or someone standing next to you, “Where are all the biotech jobs?” it’s a good thing you’re reading this now. Read More...

Judge refuses to delay Glaxo-Human Genome deal
The Daily Record
A federal judge in Delaware has refused to issue a restraining order delaying the acquisition of Human Genome Sciences Inc. by GlaxoSmithKline. Read More...

United Therapeutics revenue up 22%
Washington Business Journal
Silver Spring-based United Therapeutics Corp. saw higher sales of its cardiopulmonary hypertension drugs last quarter, but rising expenses left profits little changed. Read More...

Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
Press Release
Neuralstem, Inc. announced that it received a notice of issuance for patent number 12/710,097 titled: "Transplantation of Human Neural Cells for Treatment of Neurodegenerative Conditions." This patent covers both the culturing of central nervous system cells as well as their transplantation into spinal cord tissue to treat neurodegenerative conditions, including amytrophic lateral sclerosis (ALS or Lou Gehrig's disease). Neuralstem is currently conducting a Phase I safety trial of its human spinal cord stem cells in the treatment of ALS. Read More...

Novavax, Inc. (NVAX) Experimental Influenza Vaccine Meets Main Goal but Delays Further Testing
Novavax, Inc. (Nasdaq:NVAX) today reported positive top-line results from the company's Phase II clinical trial of its quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidate.  Read More....

Biotech Investor New Enterprise Associates (NEA) Raises $2.6 Billio VC Fund
New Enterprise Associates, Inc. (NEA), a leading global venture capital firm, today announced the official close of its fourteenth fund with $2.6 billion in totoal committed capital.  The fund, one of the largest venture funds ever raised, brings NEA's total committed capital to more than $13 billion across all funds. Read More...

BioHealth Innovation seeks to help Maryland companies secure more funding
Baltimore Busienss Journal
BioHealth Innovation Inc. is adding staff and office space to expand its operations in central Maryland.  Read More...

Psyadon Pharmaceuticals, Inc. Announces Positive Interim Analysis of Phase 2 Study of Ecopipam for the Treatment of Tourette Syndrome
Psyadon Pharmaceuticals, Inc. announced today that its Phase 2 study of ecopipam in patients with Tourette Syndrome was stopped early when a planned interim analysis revealed a statistically significant reduction in the severity of the patients' tic symptoms. This decision was supported by both the independent Drug Safety and Monitoring Committee overseeing the study and by the external Research Committee established as part of Psyadon's partnership with the Tourette Syndrome Association (TSA) - the nation's largest patient advocacy group for this disorder. Read More...

Novavax tackles newborn respiratory disease through mother
The idea of immunizing a pregnant woman to prevent a disease in her newborn isn’t new, but Novavax is applying the concept in a new way. Read More...

Shareholders seek to block Human Genome Sciences buyout
Washington Business Journal
Two shareholders of Rockville-based biotech firm Human Genome Sciences Inc. have filed a lawsuit to block the acquisition by GlaxoSmithKline.

GlaxoSmithKline to acquire Human Genome Sciences after raising bid to $3.6 billion
British drugmaker GlaxoSmithKline has agreed to pay $3.6 billion for Rockville-based Human Genome Sciences after a months-long buyout dispute, marking the largest sticker price for a local biotechnology acquisition in five years. The deal brings an end to what had become an increasingly heated battle for control of the life sciences company, one of the region’s highest-profile biotechnology firms. Read More...

GlaxoSmithKline to Acquire Human Genome Sciences For $3.6B

GlaxoSmithKline plc
has agreed to acquire Human Genome Sciences for $14.25 per share in cash in a deal that values HGS at approximately $3.6 billion on an equity basis, or approximately $3 billion net of cash and debt, and represents a premium of 99% to the HGS closing price of $7.17 per share on 18 April 2012, the last day of trading before HGS publicly disclosed GSK’s initial private offer. Read More…

GSK to acquire Human Genome Sciences for US$14.25 per share in cash
Yahoo News
GlaxoSmithKline plc and Human Genome Sciences today announced that the companies have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. Read More…

Biomedica M Corp Announces IND Filing
Biomedica Management Corporation today announced that it has submitted an Investigational New Drug Application with the U.S. Food and Drug Administration (FDA) for approval to test its novel second generation hemostatic agent ClotFoam® as an adjunct to general hemostasis. Read More....


Therapeutic cancer vaccines: Optimism for the future at BIO 2012
There has been a lot of talk about vaccines for cancer, and the move to market has seemed a little slow, with only one on the market so far--Dendreon's Provenge, for prostate cancer.  However, the field is still very active... Read More...

Rockville biotech snags $220M for biodefense center
Emergent BioSolutions, the Rockville biotech that sells the only approved anthrax vaccine to the federal government, has won a $220 million grant to establish a new biodefense development and manufacturing center in Maryland. Read More...

ImQuest: the HIV patch
If Robert W. Buckheit Jr. and his team have their way HIV and AIDS sufferers will one day be able to control their diseases, in part, much in the same way some smokers kick their cigarette habits. Read More...

GenVec gets first approved product
Washington Business Journal
Gaithersburg-based GenVec Inc. has received Department of Agriculture approval for a conditional license for its foot-and-mouth disease vaccine for use in cattle. Read More...

NIH looking to build iPad, iPhone apps
The National Institutes of Health issued a request for information seeking a pool of developers to create mobile applications for Apple’s iPad and iPhone.


Gaithersburg drug-maker signs deal for European market
Wellstat Therapeutics is selling to a London company certain rights, plus an option for marketing rights, for its experimental drug used as an antidote in cancer chemotherapy. Read More...

GenVec names Cynthia Collins new CEO
Washington Business Journal
Gaithersburg-based vaccine developer GenVec Inc., whose chief executive Paul Fischer announced plans to retire in December, has named industry veteran Cynthia Collins as president and CEO. Read More...

Emergent BioSolutions approves $35 million stock buyback
Washington Business Journal
Rockville-based Emergent BioSolutions Inc. has launched a share repurchase program for up to $35 million of the company’s common stock. Read More...

GlycoMimetics, partners developing AIDS vaccine
GlycoMimetics will work with the nonprofit International AIDS Vaccine Initiative and Glycosensors and Diagnostics LLC on the vaccine that will use compounds that mimic carbohydrates, called glycomimetics.

Emergent gets FDA approval for modified vaccine dosing
Washington Business Journal
Rockville-based Emergent BioSolutions Inc. which makes the only vaccine licensed by the Food and Drug Administration to protect against anthrax infection, has received FDA approval for a new, shorter-dosing schedule.

Human Genome Sciences enters talks with potential suitors
The Daily Record
Human Genome Sciences Inc. entered into confidentiality agreements with “certain parties” and is providing an opportunity to engage in due diligence reviews, the Rockville-based company said Thursday. Read More...

World's First Approved Stem Cell Drug; Osiris Receives Marketing Clearance from Health Canada for Prochymal
Press Release
Osiris Therapeutics Inc. announced today it has received market authorization from Health Canada to market its stem cell therapy Prochymal® (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.

Sucampo Pharmaceuticals cuts losses
Washington Business Journal
Bethesda-based Sucampo Pharmaceuticals Inc., with one drug to treat bowel dysfunction on the market and another heading toward a regulatory review, cut losses last quarter on lower research and development costs. Read More...

EntreMed keeps its listing
Washington Business Journal
Rockville-based EntreMed Inc. which was warned in November it was at risk of losing its Nasdaq stock market listing, will now keep it. Read More...

GenVec revenue falls, loss widens
Washington Business Journal
Gaithersburg-based GenVec Inc. posted a wider loss in its latest quarter as cost reductions failed to make up for a drop in revenue. Read More...

Biowatch: Supernus debuts on the Nasdaq, awaits ruling on epilepsy drugs
Supernus Pharmaceuticals, the Rockville biotech that’s developing drugs to treat epilepsy, depression and attention deficit hyperactivity disorder, got off to a solid start in its first week of trading as a public company.

BioMed adds two Rockville buildings in $26.2M deal
BioMed Realty Trust of San Diego has announced plans to buy two more Rockville laboratory and office buildings for $26.2 million. Read More...

Supernus moves from IPO to FDA
Washington Business Journal
Supernus Pharmaceuticals Inc. capped off its first week on the Nasdaq up nearly $1 from its initial public offering price. With its IPO in the bag, the Rockville biotech now turns to a bigger gamble: seeing two drugs through Food and Drug Administration approval and onto the commercial market. Read More...


Emergent Biosolutions Executive Chairman Fuad El-Hibri Named Tech Council of Maryland's Executive of the Year
Press Release
Emergent BioSolutions Inc. announced today that Fuad El-Hibri, its executive chairman of the board, has been recognized as Executive of the Year by the Tech Council of Maryland (TCM), the state’s largest technology and life science association. Read More... 

United Therapeutics reports strong quarter
Washington Business Journal
Silver Spring-based United Therapeutics Corp., aiming for $1 billion in annual revenue by next year, is well on its way toward that mark.

Neuralstem Chief Scientific Officer To Present At Spinal Cord Injury Conference In China
Press Release
Neuralstem, Inc. (NYSE Amex: CUR) announced that Karl Johe, PhD, Chairman and Chief Scientific Officer, will present at the Fourth International Spinal Cord Injury Treatments and Trials Symposium, in Xi'an, China on Friday, May 4, at 1:00 PM.  Read More...

Proton treatment center construction to start on Baltimore's west side
Baltimore Business Journal
The University of Maryland School of Medicine and Advanced Particle Therapy LLC of San Diego plan to start construction on a new $200 million-plus proton treatment center on Baltimore’s west side.  Read More....

Cytomedix wound therapy shows promise in diabetics
Cytomedix has reported positive data from a clinical trial of its wound care therapy in Japan — and a major stock sale involving a 15.3 percent stake in the Gaithersburg biotech. Read More...

Gaithersburg offers incentive to Novavax for move
Washington Business Journal
Rockville-based Novavax Inc. is in negotiations with Gaithersburg officials on an agreement that would give the biopharmaceutical company financial incentives to help renovate about 74,000 square feet of manufacturing, lab and office space at 20 and 22 Firstfield Road, The Gazette reports. Read More...

Vital Signs by Phone, Then, With a Click, a Doctor’s Appointment
The New York Times
If ever an industry were ready for disruption, it is the American health care industry. Americans spend about $7,600 a year per person on health care, one in two adults lives with a chronic disease and the average wait time to see a doctor in a metropolitan area is 20 days. Read More...


Montgomery biotechs get $6M boost from first local tax program
Ten biotechnology companies in Montgomery County last year received almost $6 million from investors who were spurred by the state and county’s biotech investment tax credit programs, officials said Monday. Read More...

Montgomery biotechs get boost from first local tax program
Washington Business Journal
Montgomery County biotech companies received almost $6 million from investors in 2011 through the county's biotech investment tax credit program, The Gazette reported. Read More...

NOVAVAX Reports Fourth Quarter and 2011 Year-End Financial Results
Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the fourth quarter and year ended December 31, 2011. Read More...

GenVec Reports Q4 and 2011 Year-End Financial Results
Today GenVec, Inc. announced financial results for the fourth quarter and year ended December 31, 2011. For the year endedDecember 31, 2011, the Company reported a net loss of $7.4 million, or $0.58 per share, compared with a net loss of $12.3 million, or $0.97 per share, for the year ended December 31, 2010. GenVec ended the year with $26.4 million in cash, cash equivalents, and short-term investments. Read More...

United Therapeutics sues to halt generic competition
Washington Business Journal
United Therapeutics Corp. on Thursday announced a lawsuit against Sandoz Inc., Novartis’ generics arm, to block the approval of a generic version of the blood pressure drug Remodulin. Read More...

Nabi to cut staff, moves toward alternatives
Washington Business Journal
Rockville-based Nabi Biopharmaceuticals, whose hopes of a vaccine to help smokers quit were dashed by failed late-stage clinical trials, posted a $2 million fourth-quarter loss and said it will further reduce its head count. Read More...

Gates Foundation commits $220M to TB nonprofit Aeras
Washington Business Journal
The Bill & Melinda Gates Foundation has committed up to $220 million for the next five years to Rockville-based Aeras, a nonprofit dedicated to developing new vaccines for tuberculosis. Read More...

Biotech, lab property owners holding their own
Washington Business Journal
The number of office/flex sales transactions involving biotechnology, lab, and research and development space saw five quarters of growth from mid-2010 to mid-2011, according to data from CoStar Group Inc.

SEC filing: Micromet CEO, execs resign in Amgen buyout
Washington Business Journal
Micromet Inc. President and CEO Christian Itin and other executives have resigned from their leadership roles as part of the company’s $1.16 billion takeover by Amgen Inc., Micromet said in a Securities and Exchange Commission filing Wednesday. Read More...

OpGen raises another $17 million in VC
Washington Business Journal
Gaithersburg-based OpGen Inc. has raised as much as $17 million to expand sales of its flagship product, the Argus Optical Mapping System, and to broaden its services business. Read More...

Mayo Clinic Announces Collaboration on New Progranulin Blood Test for Dementia
Mayo Clinic today announced that Mayo Medical Laboratories has signed an agreement with A&G Pharmaceutical, Inc. and will receive a non-exclusive license to certain patent rights and proprietary antibody reagents for the detection and measurement of progranulin in blood. This agreement will let Mayo Clinic offer the first commercial blood test to predict progranulin mutation status in patients suspected to have frontotemporal dementia (FTD). 

Northwest Biotherapeutics, Red Cross team up on cancer vaccine
Washington Business Journal
Northwest Biotherapeutics Inc., the Bethesda biotech that’s developing a vaccine for brain cancer, is working with the American Red Crossto help obtain the blood it needs to make its DCVax-L treatments, The Gazette reported. Read More...

ack to top

  social media links

Watch MBC Deputy Director, Judy Costello
discuss the Maryland Biotechnology Center
at AdvaMed 2011

Contact the Office | Site Map | Accessibility | Privacy Note | Refund Policy | Terms Of Use   
9700 Great Seneca Highway, Rockville, MD 20850 301-762-9214   
401 East Pratt Street, 7th Floor, Baltimore, MD 21202 410-767-0505